Evaluation of Immunogenicity and Safety of VARIVAX™ New Seed Process (NSP) in Children (V210-063)

Inclusion Criteria:

- Negative clinical history for varicella, herpes zoster, measles, mumps, and rubella

Exclusion Criteria:

- Received any measles, mumps, rubella, or varicella vaccine at any time prior to the
study, or is anticipated to receive any of these vaccines outside the study

- Any congenital or acquired immune deficiency, neoplastic disease, or depressed
immunity

- Received systemic immunomodulatory steroids within 3 months prior to entering the
study or is expected to receive them during the course of the study

- History of allergy or anaphylactic reaction to neomycin, gelatin, sorbitol, egg
proteins, chicken proteins, or any component of VARIVAX™ or M-M-R II™

- Received salicylates within 14 days prior to study vaccination

- Exposed to varicella, herpes zoster, measles, mumps, or rubella in the 4 weeks prior
to study vaccination

- Received immune globulin, a blood transfusion, or blood-derived products within 5
months prior to study vaccination

- History of seizure disorder, including febrile seizure

- Fever illness (>=102.2 °F [39.0 °C] within 72 hours prior to study vaccination

- History of thrombocytopenia

- Born to a human immunodeficiency virus (HIV)-infected mother

- Participated in any other clinical trial (other than a surveillance study) within 30
days prior to study enrollment.